Review



nir178 (a2a antagonist)  (Novartis)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Novartis nir178 (a2a antagonist)
    Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.
    Nir178 (A2a Antagonist), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nir178 (a2a antagonist)/product/Novartis
    Average 90 stars, based on 1 article reviews
    nir178 (a2a antagonist) - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases"

    Article Title: Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases

    Journal: Frontiers in Physiology

    doi: 10.3389/fphys.2022.849258

    Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.
    Figure Legend Snippet: Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.

    Techniques Used: Clinical Proteomics



    Similar Products

    nir178 (a2a antagonist)  (Novartis)
    90
    Novartis nir178 (a2a antagonist)
    Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.
    Nir178 (A2a Antagonist), supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nir178 (a2a antagonist)/product/Novartis
    Average 90 stars, based on 1 article reviews
    nir178 (a2a antagonist) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    adenosine a2a receptor antagonist nir178  (Novartis)
    90
    Novartis adenosine a2a receptor antagonist nir178
    Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.
    Adenosine A2a Receptor Antagonist Nir178, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/adenosine a2a receptor antagonist nir178/product/Novartis
    Average 90 stars, based on 1 article reviews
    adenosine a2a receptor antagonist nir178 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.

    Journal: Frontiers in Physiology

    Article Title: Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases

    doi: 10.3389/fphys.2022.849258

    Figure Lengend Snippet: Clinical trials evaluating the potential use of purinergic mediators as targets for hepatopancreatobiliary tumors.

    Article Snippet: CD73 +/− A2AAR , NZV930 (anti-CD73 Ab) +/− PDR001 (anti-PD-1 Ab) +/− NIR178 (A2A antagonist) , Patients with advanced solid tumors including PDAC , NCT03549000 , Phase I/Ib , Novartis Pharmaceuticals.

    Techniques: Clinical Proteomics